Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


A Closer Look: Hutchison MediTech TCM Deal With Nestle Reaches Into Pharma Development

This article was originally published in PharmAsia News

Executive Summary

A new joint venture between Nestle Health Science and Chi-Med covering nutritional and medicinal products derived from botanical plants also includes Phase III drug HMPL-004, ending the Chinese R&D firm’s long search for a partner.


Related Content

Nestlé Health Science Plans Continuum Of Care
Nestle Gains GI Diagnostics For Nutritional Health Biz Via Prometheus Deal
Chi-Med Expected To Double Revenue By 2015, Backed By Urbanization, Healthcare Reform And TCM Performance in China
China's Hutchison MediPharma Phase IIb Trials In Ulcerative Colitis Meet Primary, Secondary Endpoints


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts